Published in Oncogene on March 16, 2006
Mitotic progression becomes irreversible in prometaphase and collapses when Wee1 and Cdc25 are inhibited. Mol Biol Cell (2011) 1.68
Functional and spatial regulation of mitotic centromere-associated kinesin by cyclin-dependent kinase 1. Mol Cell Biol (2010) 1.13
Cyclin A2-cyclin-dependent kinase 2 cooperates with the PLK1-SCFbeta-TrCP1-EMI1-anaphase-promoting complex/cyclosome axis to promote genome reduplication in the absence of mitosis. Mol Cell Biol (2009) 1.11
Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles. ACS Nano (2011) 1.09
Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth. Nucleic Acids Res (2009) 1.06
Cdk1/cyclin B1 controls Fas-mediated apoptosis by regulating caspase-8 activity. Mol Cell Biol (2010) 1.03
Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo. Am J Pathol (2011) 1.03
PCTAIRE1 phosphorylates p27 and regulates mitosis in cancer cells. Cancer Res (2014) 1.03
Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol. BMC Cancer (2008) 1.03
Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors. Cancers (Basel) (2015) 0.99
CIB1 prevents nuclear GAPDH accumulation and non-apoptotic tumor cell death via AKT and ERK signaling. Oncogene (2012) 0.91
Overexpression of cyclin B1 antagonizes chemotherapeutic-induced apoptosis through PTEN/Akt pathway in human esophageal squamous cell carcinoma cells. Cancer Biol Ther (2012) 0.90
Enhanced anti-tumour effects of Vinca alkaloids given separately from cytostatic therapies. Br J Pharmacol (2013) 0.89
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay. Oncogene (2008) 0.87
Sticky siRNAs targeting survivin and cyclin B1 exert an antitumoral effect on melanoma subcutaneous xenografts and lung metastases. BMC Cancer (2013) 0.84
Primate-specific RFPL1 gene controls cell-cycle progression through cyclin B1/Cdc2 degradation. Cell Death Differ (2010) 0.84
In vitro growth inhibition of human cancer cells by novel honokiol analogs. Bioorg Med Chem (2012) 0.81
The lethal response to Cdk1 inhibition depends on sister chromatid alignment errors generated by KIF4 and isoform 1 of PRC1. Sci Rep (2015) 0.79
Ligand stimulation of CD95 induces activation of Plk3 followed by phosphorylation of caspase-8. Cell Res (2016) 0.79
Mitotic p21Cip1/CDKN1A is regulated by cyclin-dependent kinase 1 phosphorylation. Oncotarget (2016) 0.78
Bioinformatics analysis of the target gene of fibroblast growth factor receptor 3 in bladder cancer and associated molecular mechanisms. Oncol Lett (2015) 0.78
Prognostic significance of claudin-1 and cyclin B1 protein expression in patients with hypopharyngeal squamous cell carcinoma. Oncol Lett (2016) 0.77
Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42. Neoplasia (2016) 0.76
Oncogenic role of mortalin contributes to ovarian tumorigenesis by activating the MAPK-ERK pathway. J Cell Mol Med (2016) 0.75
Suppression of HSP27 increases the anti‑tumor effects of quercetin in human leukemia U937 cells. Mol Med Rep (2015) 0.75
Epigenetic reactivation of RASSF1A by phenethyl isothiocyanate (PEITC) and promotion of apoptosis in LNCaP cells. Pharmacol Res (2016) 0.75
ARHGAP1 overexpression inhibits proliferation, migration and invasion of C-33A and SiHa cell lines. Onco Targets Ther (2017) 0.75
PRKAR2B plays an oncogenic role in the castration-resistant prostate cancer. Oncotarget (2017) 0.75
Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells. Sci Rep (2017) 0.75
The 5' terminus of the RNA moiety of U1 small nuclear ribonucleoprotein particles is required for the splicing of messenger RNA precursors. Cell (1984) 6.25
Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med (1998) 6.09
Transient neurologic toxicity after hyperbaric subarachnoid anesthesia with 5% lidocaine. Anesth Analg (1993) 4.24
Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron (1996) 4.12
Generation of histone mRNA 3' ends by endonucleolytic cleavage of the pre-mRNA in a snRNP-dependent in vitro reaction. EMBO J (1986) 3.45
Purification of two picornaviral 2A proteinases: interaction with eIF-4 gamma and influence on in vitro translation. Biochemistry (1993) 2.76
Mapping the cleavage site in protein synthesis initiation factor eIF-4 gamma of the 2A proteases from human Coxsackievirus and rhinovirus. J Biol Chem (1993) 2.70
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol (2002) 2.61
Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst (1996) 2.51
Structural basis for recognition of the intron branch site RNA by splicing factor 1. Science (2001) 2.35
Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci U S A (1994) 2.31
Heat-labile regulatory factor is required for 3' processing of histone precursor mRNAs. Proc Natl Acad Sci U S A (1987) 2.28
Interaction of mammalian splicing factor SF3a with U2 snRNP and relation of its 60-kD subunit to yeast PRP9. Science (1993) 2.27
Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene (1997) 2.25
Widespread intraspecies cross-contamination of human tumor cell lines arising at source. Int J Cancer (1999) 2.20
Mammalian splicing factor SF1 is encoded by variant cDNAs and binds to RNA. RNA (1996) 2.16
Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. J Histochem Cytochem (1986) 2.05
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet (2015) 2.05
Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res (1999) 2.01
The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 2.00
Separation of splicing factor SF3 into two components and purification of SF3a activity. J Biol Chem (1993) 2.00
In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol (2005) 1.89
Amino acid analysis at the picomole level. Application to the C-terminal sequence analysis of polypeptides. Biochem J (1981) 1.76
The polo-like protein kinases Fnk and Snk associate with a Ca(2+)- and integrin-binding protein and are regulated dynamically with synaptic plasticity. EMBO J (1999) 1.75
Different small nuclear ribonucleoprotein particles are involved in different steps of splicing complex formation. Cold Spring Harb Symp Quant Biol (1987) 1.67
Endocrine treatment options for advanced breast cancer--the role of fulvestrant. Eur J Cancer (2005) 1.65
PDZ-domain-mediated interaction of the Eph-related receptor tyrosine kinase EphB3 and the ras-binding protein AF6 depends on the kinase activity of the receptor. Proc Natl Acad Sci U S A (1998) 1.57
Purification of a protein required for the splicing of pre-mRNA and its separation from the lariat debranching enzyme. EMBO J (1985) 1.56
BioMiner--modeling, analyzing, and visualizing biochemical pathways and networks. Bioinformatics (2002) 1.55
Monoclonal immunoglobulin A antibody directed against serotype-specific epitope of Shigella flexneri lipopolysaccharide protects against murine experimental shigellosis. J Exp Med (1995) 1.54
Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol (2003) 1.53
Liquid chromatographic determination of amino acids after gas-phase hydrolysis and derivatization with (dimethylamino)azobenzenesulfonyl chloride. Anal Chem (1986) 1.52
Pretherapeutic detection of tumour resistance and the results of tumour chemotherapy. Eur J Cancer (1979) 1.49
Sexual behavior and the prevalence of Chlamydia trachomatis infection in asymptomatic students in Germany and Spain. Eur J Epidemiol (2001) 1.48
Cytokine release from placental endothelial cells, a process associated with preterm labour in the absence of intrauterine infection. Cytokine (1999) 1.44
Filgrastim post-chemotherapy mobilizes more CD34+ cells with a different antigenic profile compared with use during steady-state hematopoiesis. Bone Marrow Transplant (1994) 1.43
Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res (1997) 1.42
[Tissue microarrays. Value of immunohistochemical proliferation markers for serial investigations of head and neck cancer]. HNO (2004) 1.41
Nitrous oxide is a potent cerebrovasodilator in humans when added to isoflurane. A transcranial Doppler study. Acta Anaesthesiol Scand (1995) 1.40
P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer (1989) 1.39
Plasma levels of granulocyte colony-stimulating factor in patients after allogeneic bone marrow transplantation for chronic myeloid leukemia correlate with engraftment of transplanted marrow. Bone Marrow Transplant (1997) 1.38
PLK (polo-like kinase), a new prognostic marker for oropharyngeal carcinomas. Int J Cancer (2000) 1.37
Monoclonal antibody directed against RNA polymerase II of Drosophila melanogaster. Mol Gen Genet (1980) 1.33
Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J Clin Oncol (1992) 1.32
Expression of p16 and lack of pRB in primary small cell lung cancer. J Pathol (1999) 1.32
Beta-galactoside-binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells. Eur J Immunol (1998) 1.27
Phosphorylation of splicing factor SF1 on Ser20 by cGMP-dependent protein kinase regulates spliceosome assembly. EMBO J (1999) 1.27
Augmentation of mechanical properties in osteoporotic vertebral bones--a biomechanical investigation of vertebroplasty efficacy with different bone cements. Eur Spine J (2001) 1.24
Amino acid analysis in the picomole range by precolumn derivatization and high-performance liquid chromatography. Methods Enzymol (1983) 1.24
Identification of cis-acting intron and exon regions in influenza virus NS1 mRNA that inhibit splicing and cause the formation of aberrantly sedimenting presplicing complexes. Mol Cell Biol (1992) 1.23
[Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy]. Geburtshilfe Frauenheilkd (1994) 1.22
Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol (2007) 1.22
Structure, expression and chromosomal mapping of TKT from man and mouse: a new subclass of receptor tyrosine kinases with a factor VIII-like domain. Oncogene (1993) 1.22
Unique signal transduction of Eyk: constitutive stimulation of the JAK-STAT pathway by an oncogenic receptor-type tyrosine kinase. EMBO J (1996) 1.21
Temporal hemodynamic effects of permissive hypercapnia associated with ideal PEEP in ARDS. Am J Respir Crit Care Med (1997) 1.21
HLXB9 activates IL6 in Hodgkin lymphoma cell lines and is regulated by PI3K signalling involving E2F3. Leukemia (2005) 1.21
A splicing factor that is inactivated during in vivo heat shock is functionally equivalent to the [U4/U6.U5] triple snRNP-specific proteins. Genes Dev (1992) 1.20
Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer. Int J Cancer (1995) 1.20
Two additional protein-tyrosine kinases expressed in human lung: fourth member of the fibroblast growth factor receptor family and an intracellular protein-tyrosine kinase. Proc Natl Acad Sci U S A (1991) 1.20
In vitro synthesis of human protein synthesis initiation factor 4 gamma and its localization on 43 and 48 S initiation complexes. J Biol Chem (1994) 1.19
Surface protein expression and messenger RNA-splicing analysis of CD44 in uterine cervical cancer and normal cervical epithelium. Cancer Res (1994) 1.19
Polo-like kinase, a novel marker for cellular proliferation. Am J Pathol (1997) 1.19
Differential diagnosis of benign epithelial proliferations and carcinomas of the breast using antibodies to cytokeratins. Hum Pathol (1988) 1.19
Goserelin depot in the treatment of premenopausal advanced breast cancer. Eur J Cancer (1992) 1.17
Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer. Breast Cancer Res Treat (2008) 1.17
Breast cancer patients' expectations in respect of the physician-patient relationship and treatment management results of a survey of 617 patients. Ann Oncol (2007) 1.16
Molecular characterization of a novel, widespread nuclear protein that colocalizes with spliceosome components. Mol Biol Cell (1998) 1.14
Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J Clin Pathol (2007) 1.13
A role for SRp54 during intron bridging of small introns with pyrimidine tracts upstream of the branch point. Mol Cell Biol (1998) 1.13
Effects of flecainide on electrophysiological properties of accessory pathways in the Wolff-Parkinson-White syndrome. Eur Heart J (1983) 1.12
The anaesthesia critical incident reporting system: an experience based database. Int J Med Inform (1997) 1.12
Virus-activated CD8 T cells and lymphokine-activated NK cells express the mast cell function-associated antigen, an inhibitory C-type lectin. J Immunol (1998) 1.11
A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. Eur J Cancer (1995) 1.11
Rational combinations of siRNAs targeting Plk1 with breast cancer drugs. Oncogene (2007) 1.11
Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. Pathol Res Pract (2000) 1.10
Molecular classification of breast cancer patients by gene expression profiling. J Pathol (2001) 1.08
Diagnostic and therapeutic pleuroscopy. Experience with 127 patients. Chest (1980) 1.08
Prognostic value of pololike kinase expression in melanomas. JAMA (2000) 1.08
Differentiation of benign and malignant parotid tumors using deconvolution-based perfusion CT imaging: feasibility of the method and initial results. Eur J Radiol (2007) 1.07
Domains in human splicing factors SF3a60 and SF3a66 required for binding to SF3a120, assembly of the 17S U2 snRNP, and prespliceosome formation. Mol Cell Biol (2001) 1.07
Gender-specific health behaviors of German university students predict the interest in campus health promotion. Health Promot Int (2001) 1.06
Calcitonin: regional distribution of the hormone and its binding sites in the human brain and pituitary. Proc Natl Acad Sci U S A (1981) 1.06
Cell-cell adhesion mediated by binding of membrane-anchored ligand LERK-2 to the EPH-related receptor human embryonal kinase 2 promotes tyrosine kinase activity. J Biol Chem (1996) 1.05
Comparison of FIB-4 and APRI in Chinese HBV-infected patients with persistently normal ALT and mildly elevated ALT. J Viral Hepat (2012) 1.04
Preparation and fractionation of mammalian extracts active in pre-mRNA splicing. Methods Enzymol (1990) 1.03
Factors influencing the prognostic role of oestrogen and progesterone receptor levels in breast cancer--results of the analysis of 670 patients with 11 years of follow-up. Eur J Cancer (2002) 1.03
Differences in health complaints among university students from three European countries. Prev Med (2003) 1.03
Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma. Leukemia (2007) 1.03